A new OIG report, "Review of Less-Than-Effective Drugs in the Medicare Part D Program," examines Medicare Part D coverage of drugs the FDA approved before 1962 but subsequently found to be less than effective, and which should not be covered by Part D. The OIG found that CMS accepted $43.3 million in Medicare Part D sponsors' prescription drug event (PDE) data for calendar years 2006 and 2007 that was associated with less-than-effective drugs. While CMS claims edits identified and rejected the vast majority of PDE data associated with less-than-effective drugs, it missed some drugs because of incomplete data (the OIG notes that there is no definitive list of less-than-effective drugs). The OIG recommended that CMS determine whether it can impose financial adjustments on sponsors that were paid for furnishing less-than-effective drugs. The OIG also recommends that CMS collaborate with FDA to create and maintain a comprehensive list of less-than-effective drugs, regularly disseminate this list to all sponsors, and use this list to reject PDE data for less-than-effective drugs.